Overview
Over the past few years, scientists shifted focus to treating breast cancer with hormonal therapies. This is especially the case when cancer spreads to other tissues. In this situation, surgery and radiation therapy are less effective, leaving chemotherapy and hormonal therapy as the only viable options.
Elacestrant is one of the studied molecules that could potentially help in the management of advanced cases of breast cancer.
In this article, we will cover the new evidence for the effectiveness of this dug in treating metastatic breast cancer.
What is Elacestrant?
Elacestrant is a nonsteroidal compound that modulates and degrades estrogen receptors. It is part of the selective estrogen receptor degrader (SERD) family.
Because breast cancer tissue has an abundance of estrogen receptors, modulating their action could be quite beneficial for metastatic cases.
How does Elacestrant work?
As part of the SERD family, Elacestrant works by binding to estrogen receptors. The drug could either stimulate or block receptor activity, depending on the tissue.
This could be very helpful in the management of estrogen receptor (ER) positive breast cancer. The activation of these receptors could be responsible for cancer proliferation.
New evidence for the effectiveness of Elacestrant in metastatic condition
Elacestrant seems to yield positive results in patients with ER-positive, HER2-negative metastatic breast cancer.
The treatment was tested in phase III clinical trial, where Elacestrant was given orally to patients. The purpose of the study was to compare the clinical outcomes of this drug relative to standard of care.
The trial enrolled 466 patients, where 220 of them had tumors with ESR1 positive mutation.
The control arm received the following:
- 500 mg of intramuscular fulvestrant
- 1 mg of anastrozole per day
- 5 mg of letrozole per day
- 25 mg of exemestane per day
Primary and secondary endpoints were the time until progression of the disease and survival, respectively.
Fortunately, the study met the primary endpoints, with a 30% risk reduction in progression or death. In the selected patients with ESR1-positive mutations, the risk reduction reached 45%.
After 12 months of follow-up, the 22.32% of patients with Elacestrant had no disease progression compared to 9.42% with standard care. The final analysis of the Survival is expected to be released in the next few months.
Finally, the safety of this therapy was consistent with the findings of previous clinical trials.
Takeaway message
The results of this study are quite promising for patients with metastatic breast cancer. In the next few months, we expect this drug to receive more attention from the scientific community for the management of advanced breast cancer.
We hope that this article helped you appreciate the potential role of Elacestrant in the management of metastatic breast cancer.
Speak with your doctor to see whether you are a candidate for this treatment.
Talk to us so see if we can help you to actually get the most advanced treatments
TRIAL•IN Pharma
Because we, do not give up on life!
Contact us 24/7 –
Call center +44.2082.426.039
Learn more about Breast cancer >>
